Literature DB >> 24696217

Therapeutic options for nocturnal problems in Parkinson's disease and atypical parkinsonian disorders.

Lisa Klingelhoefer1, Elisaveta Sokolov, K Ray Chaudhuri.   

Abstract

Sleep disturbances in Parkinson's disease and parkinsonism (such as atypical parkinsonian disorders like multiple system atrophy, progressive supranuclear palsy, dementia with Lewy bodies and corticobasal degeneration) are multifactorial and as such treatment needs to be tailored to the specific patient case and sleep dysfunction. One also has to consider drug-related effects on sleep architecture. This article provides an overview of the therapeutic options for nocturnal problems in Parkinson`s disease and atypical parkinsonian disorders.

Entities:  

Mesh：

Year:  2014        PMID： 24696217     DOI： 10.1007/s00702-014-1202-6

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  57 in total

Review 1.  The basis for day and night-time control of symptoms of Parkinson's disease.

Authors:  K Ray Chaudhuri
Journal:  Eur J Neurol       Date:  2002-11       Impact factor: 6.089

2.  Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial.

Authors:  Anthony H V Schapira; P Barone; R A Hauser; Y Mizuno; O Rascol; M Busse; L Salin; N Juhel; W Poewe
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

3.  Parkinson's disease symptoms: the patient's perspective.

Authors:  Marios Politis; Kit Wu; Sophie Molloy; Peter G Bain; K Ray Chaudhuri; Paola Piccini
Journal:  Mov Disord       Date:  2010-08-15       Impact factor: 10.338

4.  European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society.

Authors:  Diego Garcia-Borreguero; Luigi Ferini-Strambi; Ralf Kohnen; Shaun O'Keeffe; Claudia Trenkwalder; Birgit Högl; Heike Benes; Poul Jennum; Markku Partinen; Danyal Fer; Pasquale Montagna; Claudio L Bassetti; Alex Iranzo; Karel Sonka; Anne-Marie Williams
Journal:  Eur J Neurol       Date:  2012-09-03       Impact factor: 6.089

5.  Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

Authors:  R Pahwa; M A Stacy; S A Factor; K E Lyons; F Stocchi; B P Hersh; L W Elmer; D D Truong; N L Earl
Journal:  Neurology       Date:  2007-04-03       Impact factor: 9.910

6.  Subclinical REM sleep behavior disorder in a patient with corticobasal degeneration.

Authors:  K Kimura; N Tachibana; T Aso; J Kimura; H Shibasaki
Journal:  Sleep       Date:  1997-10       Impact factor: 5.849

7.  Sleep and quantitative EEG in patients with progressive supranuclear palsy.

Authors:  J Montplaisir; D Petit; A Décary; H Masson; M A Bédard; M Panisset; G Rémillard; S Gauthier
Journal:  Neurology       Date:  1997-10       Impact factor: 9.910

8.  Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

Authors:  William G Ondo; Thomas Perkins; Todd Swick; Keith L Hull; J Ernesto Jimenez; Tippy S Garris; Daniel Pardi
Journal:  Arch Neurol       Date:  2008-10

9.  A new method for measuring daytime sleepiness: the Epworth sleepiness scale.

Authors:  M W Johns
Journal:  Sleep       Date:  1991-12       Impact factor: 5.849

10.  Daytime sleepiness in Japanese patients with multiple system atrophy: prevalence and determinants.

Authors:  Takayoshi Shimohata; Hideaki Nakayama; Masahiko Tomita; Tetsutaro Ozawa; Masatoyo Nishizawa
Journal:  BMC Neurol       Date:  2012-11-01       Impact factor: 2.474
View more
  3 in total

Review 1.  Parkinson's disease as a multisystem disorder.

Authors:  Lisa Klingelhoefer; H Reichmann
Journal:  J Neural Transm (Vienna)       Date:  2017-02-02       Impact factor: 3.575

Review 2.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

3.  Treatment of sleeping disorders should be considered in clinical management of Parkinson's disease.

Authors:  Altair Brito Dos Santos; George E Barreto; Kristi A Kohlmeier
Journal:  Front Aging Neurosci       Date:  2014-10-09       Impact factor: 5.750
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.